THREE STUDIES REPORTING INCREASED RISK WITH ANTIHYPERTENSIVE DRUGS
Slide 49 of 75
Go to slide:
1: OBJECTIVES
2: OF PILLS AND POTIONS
3: (Untitled)
4: (Untitled)
5: (Untitled)
6: (Untitled)
7: (Untitled)
8: (Untitled)
9: (Untitled)
10: (Untitled)
11: (Untitled)
12: (Untitled)
13: INTRACELLULAR Ca++ FUNCTIONS
14: Calcium Balance Chart
15: (Untitled)
16: (Untitled)
17: Cell Structure Chart
18: PROPOSED THAT TWO CALCIUM CHANNELS EXIST
19: RECEPTOR OPERATED CHANNEL
20: VOLTAGE SENSITIVE CHANNEL
21: (Untitled)
22: (Untitled)
23: CALCIUM CHANNEL ANTAGONISTS
24: (Untitled)
25: CALCIUM CHANNEL ANTAGONISTS
26: (Untitled)
27: (Untitled)
28: (Untitled)
29: (Untitled)
30: FIRST GENERATION CALCIUM CHANNEL ANTAGONISTS
31: (Untitled)
32: (Untitled)
33: (Untitled)
34: (Untitled)
35: (Untitled)
36: SECOND GENERATION AGENTS
37: (Untitled)
38: CONGESTIVE HEART FAILURE
39: SECOND GENERATION CALCIUM CHANNEL ANTAGONISTS
40: SECOND GENERATION AGENTS
41: (Untitled)
42: (Untitled)
43: (Untitled)
44: (Untitled)
45: (Untitled)
46: (Untitled)
47: TIGHT HYPERTENSIVE CONTROL
48: TIGHT HYPERTENSIVE CONTROL
49: THREE STUDIES REPORTING INCREASED RISK WITH ANTIHYPERTENSIVE DRUGS
50: SECOND GENERATION AGENTS
51: SECOND GENERATION AGENTS
52: (Untitled)
53: (Untitled)
54: (Untitled)
55: DRUGS METABOLIZED BY CYP 3A3/4
56: DRUGS INHIBITING
57: (Untitled)
58: CALCIUM CHANNEL ANTAGONISTS
59: (Untitled)
60: (Untitled)
61: L-type Channel Model
62: (Untitled)
63: (Untitled)
64: (Untitled)
65: (Untitled)
66: Calcium Balance Chart
67: Calcium Balance Chart
68: (Untitled)
69: (Untitled)
70: (Untitled)
71: SECOND GENERATION AGENTS
72: (Untitled)
73: (Untitled)
74: (Untitled)
75: FIRST GENERATION AGENTS
